Alzheimer’s digest - 2021

Alzheimer’s digest - 2021

Galimedix accelerating development for GAL-201

GAL-201 (Anti amyloid-β) – Galimedix

  • Galimedix announced an accelerated program for its oral small molecule GAL-201 targeting amyloid-β oligomers
  • Planning for FIH within one year
  • In preclinical studies, GAL-201 has shown to prevent and even reverse the synapto-toxic effects of Aβ oligomers on hippocampal LTP even at acutely pharmacologically inactive final concentrations following serial dilution (For full story click here)

Galmedix plans to initiate FIH trial within the year

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share

CI Scientists Commentary:

  • Galimedix is prioritizing its preclinical asset, GAL-201 (anti-amyloid) over its clinical asset GAL-101
  • A likely reason for this prioritization is the recent FDA approval of Biogen’s Aduhelm which targets amyloid-β
  • About GAL-201: It is a small molecule inhibitor of amyloid-β This is a next-generation molecule derived from GAL-101 (in development for glaucoma and AMD) with improved pharmacology and pharmacokinetics
  • With antibodies showing debatable benefit, this small molecule on proven efficacy may have an impact

– Dr. Kowndinya, CI Scientists

Home